Compare Stocks

→ Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LCI Lannett		$1.54	$0.64 ▼ $3.72	$7.38M	0.95	92,067 shs	280,600 shs
LXRX Lexicon Pharmaceuticals	$1.60 -0.6%	$2.31	$0.92 ▼ $3.79	$393.98M	1.27	4.41 million shs	1.76 million shs
MRSN Mersana Therapeutics	$2.88 -10.3%	$4.44	$0.80 ▼ $9.62	$349.35M	1.5	2.22 million shs	3.22 million shs
OSMT Osmotica Pharmaceuticals		$1.16	$0.98 ▼ $4.95	$69.47M	2.34	396,682 shs	296,500 shs
REPH Recro Pharma		$1.73	$1.38 ▼ $3.79	$117.93M	1.08	126,298 shs	141,800 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LCI Lannett	0.00%	0.00%	0.00%	0.00%	0.00%
LXRX Lexicon Pharmaceuticals	-5.85%	-5.01%	-28.76%	-6.94%	-32.07%
MRSN Mersana Therapeutics	+1.90%	-14.63%	-31.70%	+2.56%	-22.65%
OSMT Osmotica Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
REPH Recro Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Pentagon contract could send this $2 AI stock soaring (Ad)

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

Get all the info here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LCI Lannett	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	0.9608 of 5 stars	3.0	1.0	0.0	0.0	1.7	1.7	0.6
MRSN Mersana Therapeutics	4.1514 of 5 stars	4.4	1.0	0.0	4.1	2.8	2.5	0.0
OSMT Osmotica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LCI Lannett	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	2.00	Hold	$5.00	212.50% Upside
MRSN Mersana Therapeutics	2.71	Moderate Buy	$6.29	118.25% Upside
OSMT Osmotica Pharmaceuticals	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest LXRX, MRSN, OSMT, REPH, and LCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/23/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
4/11/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
3/19/2024	MRSN Mersana Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$5.00
2/29/2024	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$9.00
2/29/2024	MRSN Mersana Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$1.00 ➝ $5.00
2/29/2024	MRSN Mersana Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$6.00
2/29/2024	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$7.00
2/29/2024	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.00 ➝ $7.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LCI Lannett	$340.58M	0.00	N/A	N/A	($23.34) per share	0.00
LXRX Lexicon Pharmaceuticals	$1.20M	328.32	N/A	N/A	$0.38 per share	4.21
MRSN Mersana Therapeutics	$36.86M	9.48	N/A	N/A	$0.31 per share	9.29
OSMT Osmotica Pharmaceuticals	$177.88M	0.00	N/A	1.00	$1.50 per share	0.00
REPH Recro Pharma	$75.36M	0.00	N/A	N/A	$0.90 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LCI Lannett	-$231.62M	-$18.88	N/A	N/A	N/A	-62.40%	N/A	-13.39%	N/A
LXRX Lexicon Pharmaceuticals	-$177.12M	-$0.80	N/A	N/A	N/A	-14,573.20%	-138.54%	-71.29%	5/7/2024 (Estimated)
MRSN Mersana Therapeutics	-$171.67M	-$1.50	N/A	N/A	N/A	-465.80%	-282.36%	-62.64%	5/14/2024 (Estimated)
OSMT Osmotica Pharmaceuticals	-$79.59M	-$1.59	N/A	N/A	N/A	-138.76%	-81.23%	-20.97%	N/A
REPH Recro Pharma	-$11.37M	-$0.31	N/A	N/A	N/A	-15.15%	-56.66%	-11.14%	N/A

Latest LXRX, MRSN, OSMT, REPH, and LCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/11/2024	Q4 2023	LXRX Lexicon Pharmaceuticals	-$0.23	-$0.20	+$0.03	-$0.20	$0.68 million	$0.70 million
2/28/2024	12/31/2023	MRSN Mersana Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$22.59 million	$10.70 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LCI Lannett	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
OSMT Osmotica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LCI Lannett	N/A	2.23	1.39
LXRX Lexicon Pharmaceuticals	1.07	5.60	5.58
MRSN Mersana Therapeutics	0.63	3.36	3.36
OSMT Osmotica Pharmaceuticals	N/A	0.43	0.42
REPH Recro Pharma	2.27	3.24	2.74

Ownership

Institutional Ownership

Company	Institutional Ownership
LCI Lannett	40.28%
LXRX Lexicon Pharmaceuticals	74.70%
MRSN Mersana Therapeutics	93.92%
OSMT Osmotica Pharmaceuticals	46.18%
REPH Recro Pharma	62.34%

Insider Ownership

Company	Insider Ownership
LCI Lannett	13.12%
LXRX Lexicon Pharmaceuticals	4.50%
MRSN Mersana Therapeutics	12.50%
OSMT Osmotica Pharmaceuticals	5.22%
REPH Recro Pharma	14.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
LCI Lannett	810	10.77 million	9.35 million	Optionable
LXRX Lexicon Pharmaceuticals	285	246.24 million	235.16 million	Optionable
MRSN Mersana Therapeutics	123	121.30 million	106.14 million	Optionable
OSMT Osmotica Pharmaceuticals	302	62.59 million	59.32 million	Not Optionable
REPH Recro Pharma	185	56.42 million	48.41 million	Optionable

LXRX, MRSN, OSMT, REPH, and LCI Headlines

Source	Headline
	Dorf Ketal's Indian unit acquires veterinary pharma brand vccircle.com - April 10 at 10:57 PM
	Fuji Pharma Co. Ltd. wsj.com - January 30 at 3:34 PM
	Aurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 crore moneycontrol.com - November 22 at 10:47 PM
	Retaining the human element of AI within pharma and healthcare pharmaphorum.com - November 21 at 10:06 AM
	Here's what Wall Street expects from Recro Pharma's earnings report markets.businessinsider.com - November 7 at 12:00 PM
	US supreme court halts Purdue Pharma deal that shields Sacklers from lawsuits theguardian.com - August 16 at 1:59 AM
	Mankind Pharma share price livemint.com - August 9 at 12:30 PM
	What Wall Street expects from Recro Pharma's earnings markets.businessinsider.com - August 9 at 7:25 AM
	Mankind Pharma Ltd (MNKI) investing.com - August 3 at 9:00 AM
	Eversana and Amazon plan generative AI push in pharma pharmaphorum.com - July 30 at 11:21 PM
	Aurobindo Pharma Ltd. ndtv.com - July 25 at 12:39 AM
	Baudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumps bizjournals.com - June 30 at 12:44 PM
	Pharma reform: Patients can’t afford to wait. Act now. politico.eu - June 13 at 3:41 PM
	Sun Pharma reports "information security incident"; isolates impacted IT assets health.economictimes.indiatimes.com - March 9 at 7:26 AM
	Watch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNL ijr.com - March 2 at 12:30 AM
	Aurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividend moneycontrol.com - February 17 at 8:43 PM
	Paytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focus financialexpress.com - December 20 at 8:48 AM
	Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTL benzinga.com - June 24 at 9:08 AM
	Societal CDMO Inc reuters.com - April 20 at 9:24 AM
	Recro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation finanznachrichten.de - March 22 at 10:51 PM
	Recro Pharma Rebrands to Societal CDMO Inc. contractpharma.com - March 22 at 5:51 PM
	Is Recro Pharma (REPH) a Worthy Investment? finance.yahoo.com - March 22 at 8:32 AM
	Recap: Recro Pharma Q4 Earnings benzinga.com - March 1 at 11:55 PM
	Recro Pharma Progresses Addition of Fill/Finish, Lyophilization Capabilities contractpharma.com - February 23 at 9:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Lannett

NYSE:LCI

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.

Lexicon Pharmaceuticals

NASDAQ:LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Mersana Therapeutics

NASDAQ:MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Osmotica Pharmaceuticals

NASDAQ:OSMT

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Recro Pharma

NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial